Parkinson’s Disease – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms – Claims Data Analysis (US)


Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including dopamine precursors, dopamine agonists, and MAO-B inhibitors. PD treatment requires individualized care, a high degree of polypharmacy, and frequent adjustments as patients advance through lines of therapy. A growing number of branded agents targeted at niche subpopulations with high unmet needs (e.g., Kynmobi [Sunovion], Gocovri [Supernus], Nourianz [Kyowa Kirin]) are entering a market dominated by entrenched, generic standards of care. With the market poised to further expand as a result of a pipeline of unique therapies offering potential clinical improvements, understanding the treatment dynamics in competitive segments of the PD therapy market will be crucial for drug developers and marketers of in-line products.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PD patients?
  • How has Xadago been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of PD patients progress to later lines of therapy within two years of diagnosis?
  • What percentage of PD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: AbbVie, Acadia, Acorda, Amneal, Kyowa Kirin, Lundbeck, Neurocrine, Sunovion, Supernus

Key drugs: Duopa, Gocovri, Inbrija, Kynmobi, Neupro, Northera, Nourianz, Nuplazid, Ongentys, Rytary, Xadago, all generic mainstays


The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.

launch Related Market Assessment Reports